Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Biogen event seeded more than 300,000 COVID-19 infections: Study 

By Brian Buntz | December 16, 2020

coronavirus COVID-19 Pfizer

[Photo by Fusion Medical Animation on Unsplash]

A recent study linked an annual management conference in Boston from Biogen (NSDQ:BIIB) to hundreds of thousands of SARS-CoV-2 infections.

Published in Science, the study concluded that the superspreader event “produced sustained community transmission and was exported, resulting in extensive regional, national, and international spread.”

Following the event, 99 people contracted the virus, including employees and their contacts, following the two-day event.

But after that, the COVID-19 two strains that spread among conference attendees dispersed across the world. A variant of the virus known as C2416T infected an estimated 245,000 people as of November 1. A European conference attendee likely imported that strain, which had not previously been detected in Massachusetts.

Another mutation tied to the conference, known as G26233T, infected an additional approximately 88,000 people.

Using a genomic epidemiology approach, the study authors analyzed 772 SARS-COV-2 genomes. Scientists from Harvard, MIT and Massachusetts General Hospital, led the research.

When the conference was held, there were only 30 confirmed COVID-19 infections in the U.S., according to the New York Times.

Biogen recently released a statement citing its role in advancing COVID-19 science and helping others afflicted by the virus in other ways. The company, for instance, is working with the Broad Institute of MIT and Harvard and Partners HealthCare to create a COVID-19-related biobank.

“Many Biogen colleagues have been eager to find ways to help others during this pandemic, and it is our hope that this biobank will provide hope and essential information during this difficult time,” said Dr. Maha Radhakrishnan, chief medical officer at the company.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Novartis logo
Novartis mulls sale of $25 billion Sandoz generics arm
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Zantac
First Zantac trial slated for February 2023

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards